Why is semaglutide dosed on a titration schedule?
Semaglutide is a GLP-1 receptor agonist. It works by mimicking the glucagon-like peptide-1 hormone, which slows gastric emptying, reduces appetite signaling, and supports the body’s satiety mechanisms. Because these actions can cause nausea and gastrointestinal discomfort at higher doses, clinical protocols universally start low and increase gradually — a process called titration.
The titration principle is not unique to semaglutide. It applies to most medications whose therapeutic window requires a period of physiological adaptation. The goal is to let your GI tract and appetite-regulation systems adjust at each dose level before advancing. Patients who skip titration steps or advance too quickly tend to experience significantly more side effects without any meaningful gain in efficacy.
What is the standard semaglutide dosage chart?
The table below reflects the titration framework studied in the STEP clinical trials and commonly used in physician-supervised compounded semaglutide protocols. Compounded semaglutide is not FDA-approved and is prescribed by a licensed clinician on a patient-specific basis; your actual schedule may differ from what is shown here.
| Weeks | Dose | Phase |
|---|---|---|
| 1–4 | 0.25 mg / week | Initiation |
| 5–8 | 0.5 mg / week | Titration step 1 |
| 9–12 | 1.0 mg / week | Titration step 2 |
| 13–16 | 1.7 mg / week | Titration step 3 |
| 17+ | 2.4 mg / week | Maintenance (if indicated) |
Important: This table is educational only. Compounded semaglutide is prescribed by a licensed clinician and is not FDA-approved. Your clinician determines the appropriate dose and schedule based on your individual health profile, goals, and response to treatment.
How do clinicians adjust the titration pace?
The chart above is a framework, not a rigid protocol. In clinical practice, two things frequently alter the pace:
Tolerance-based slowing
If you experience persistent nausea, vomiting, or significant GI discomfort at a given dose, your clinician will typically hold you at that dose for an additional four weeks — or sometimes longer — rather than advancing on schedule. There is no clinical benefit to accelerating through discomfort. The GI side effects of GLP-1 receptor agonists are dose-dependent and time-limited in most patients; staying at a dose until your body adapts is the standard of care.
Goal-based maintenance at an intermediate dose
Not everyone needs or tolerates the maximum 2.4 mg dose. A substantial proportion of patients in clinical practice reach their weight management goals at 1.0 or 1.7 mg and elect to remain there with their clinician’s guidance. Advancing to a higher dose when a lower dose is working well and causing minimal side effects offers no demonstrated advantage. Your clinician evaluates your progress at each check-in and adjusts accordingly.
What should you expect at each dose level?
0.25 mg (weeks 1–4)
The initiation dose is pharmacologically sub-therapeutic for most patients — its purpose is tolerance-building, not weight management effect. Some patients notice mild appetite suppression and occasional nausea, particularly in the first day or two after each injection. Most patients feel little effect at this stage and sometimes worry the medication isn’t working. This is expected. The clinical benefit develops as doses increase.
0.5–1.0 mg (weeks 5–12)
This is where most patients begin to notice meaningful appetite changes — reduced hunger, earlier satiety, and a decreased preoccupation with food between meals. GI side effects, if present, are typically most pronounced in the first week at each new dose and diminish as the body adjusts.
1.7–2.4 mg (weeks 13+)
Higher doses tend to produce stronger appetite suppression. The clinical trial data for weight management was gathered primarily at the 2.4 mg maintenance dose. At this level, some patients report reduced interest in foods they previously enjoyed, a phenomenon sometimes called “food noise reduction.” GI tolerability varies considerably at this range — some patients do very well, others prefer to remain at 1.0 or 1.7 mg.
How and when should you inject semaglutide?
Semaglutide is administered once per week, on the same day each week, via subcutaneous injection — meaning the injection goes into the tissue just below the skin, not into muscle. Common injection sites include the abdomen, upper thigh, and upper arm. Your clinician or the materials provided with your compounded medication will include specific injection guidance.
Consistency of timing matters primarily for routine adherence, not pharmacology. Semaglutide has a half-life of approximately one week, so once-weekly dosing maintains stable drug levels. A one- or two-day variation in injection day generally does not alter clinical outcomes, but a consistent weekly routine reduces missed doses.
Where is compounded semaglutide sourced, and is it safe?
PepScribe prescribes compounded semaglutide prepared by licensed 503A pharmacies in the United States. Compounded medications are patient-specific preparations that are not FDA-approved as finished drug products, but 503A compounding pharmacies operate under state pharmacy board oversight and must meet USP standards for sterility and quality.
Every dose dispensed through PepScribe is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. This matters because the gray market for GLP-1 medications includes unregulated products with unknown purity, incorrect concentrations, and no sterility standards — risks that physician-supervised compounding is specifically designed to eliminate.
Frequently asked questions
What is the starting semaglutide dosage for weight management?
Most clinicians start compounded semaglutide at 0.25 mg injected subcutaneously once per week for the first four weeks. This low starting dose is designed to minimize gastrointestinal side effects while the body acclimates to the medication.
How long does a semaglutide dosage titration take?
A standard titration schedule runs 16–20 weeks from the initial 0.25 mg dose to a maintenance dose, though timelines vary. Many patients remain at an intermediate dose (0.5–1.0 mg) rather than advancing to the maximum, because their goals and tolerance are well-matched at that level.
Can a clinician keep me at a lower semaglutide dose?
Yes. There is no clinical mandate to advance to a higher dose. If a patient is meeting their weight management goals and tolerating a dose well, staying at that dose is a legitimate clinical decision. Your prescribing clinician will guide this based on your check-in responses.
What semaglutide dosage is used for weight management vs. other uses?
Compounded semaglutide for weight management typically follows the same dose-escalation logic as the branded injectable formulations studied in clinical trials — starting low and titrating upward every four weeks based on tolerance. Your clinician determines the appropriate dose range for your specific goals.
Is the semaglutide dosage chart the same for everyone?
No. The chart below reflects a common starting framework, but clinicians adjust the pace of titration based on each patient's response, tolerability, and progress. Patients who experience significant nausea may stay at a lower dose longer.
What happens if I miss a semaglutide dose?
If you miss a dose, administer it as soon as you remember — provided it is within five days of the scheduled day. If more than five days have passed, skip that dose and resume your regular weekly schedule. Never double-dose. Contact your clinician if you are unsure.